Primary lymphoma of CNS, mycophenolate mofetil and lupus.
Lymphoproliferative disorders are known to complicate immunosuppressive therapy and two cases of primary lymphoma of CNS (PCNSL) have previously been described in association with mycophenolate mofetil (MMF) treatment. We report the third case of PCNSL in a patient with lupus nephropathy while on MMF treatment. PCNSL may be seen more frequently considering the increased use of MMF in immunosuppressant responsive conditions.
Finelli
P F
PF
Department of Neurology, Hartford Hospital and University of Connecticut School of Medicine, Hartford, CT 06102-5037, USA. pfinell@harthosp.org
Naik
K
K
DiGiuseppe
J A
JA
Prasad
A
A
D000328:Adult; D016543:Central Nervous System Neoplasms / Q000139:chemically induced* / Q000473:pathology; D038524:Diffusion Magnetic Resonance Imaging; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D007165:Immunosuppression Therapy / Q000009:adverse effects; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects*; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy*; D008223:Lymphoma / Q000139:chemically induced* / Q000473:pathology; D009173:Mycophenolic Acid / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*
D007166:Immunosuppressive Agents; D009173:Mycophenolic Acid